Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - chlorhydrate de doxorubicine 2 mg/ml - solution à diluer pour perfusion - 2 mg/ml - chlorhydrate de doxorubicine 2 mg/ml - doxorubicin

Union européenne - français - EMA (European Medicines Agency)

tlc biopharmaceuticals b.v. - chlorhydrate de doxorubicine - breast neoplasms; ovarian neoplasms - agents antinéoplasiques - traitement du cancer du sein et le cancer de l'ovaire.

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - solution injectable - doxorubicini hydrochloridum 10 mg, natrii chloridum corresp. natrium 17.7 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 5 ml. - cytostatique - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - solution injectable - doxorubicini hydrochloridum 20 mg, natrii chloridum corresp. natrium 35.4 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 10 ml. - cytostatique - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - solution injectable - doxorubicini hydrochloridum 50 mg, natrii chloridum corresp. natrium 88.5 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 25 ml. - cytostatique - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - solution injectable - doxorubicini hydrochloridum 100 mg, natrii chloridum corresp. natrium 177 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 50 ml. - cytostatique - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - doxorubicini hydrochloridum - solution injectable - doxorubicini hydrochloridum 200 mg, natrii chloridum corresp. natrium 354 mg, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 100 ml. - cytostatique - synthetika

Union européenne - français - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - chlorhydrate de doxorubicine - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agents antinéoplasiques - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

pfizer holding france - doxorubicine - solution injectable pour perfusion - 50 mg/25 ml - antineoplasiques et immunomodulateurs - antineoplasiques - - carcinomes du sein. - sarcomes des os et des parties molles. - maladie de hodgkin, lymphomes non hodgkiniens. - tumeurs solides de l'enfant. - cancers du poumon. - leucémies aiguës et chroniques. - cancers de la vessie, de l'ovaire, de l'estomac.